Views & Analysis Transparently opaque: drug list prices versus net prices The pros and cons of keeping drug pricing agreements confidential.
News FDA accelerated approval path needs improvement, says ICER The FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
